As drugs like Ozempic, Rybelsus, and Wegovy gain attention for treating diabetes and supporting weight loss, researchers are exploring how they might affect other conditions, including liver disease. In this faculty Q&A, Michigan Medicine hepatologist Robert Fontana, M.D., discusses the growing interest in GLP-1 drugs and what doctors are watching for as research continues.
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.